2024-518069-89-00招募中2 期
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after Olaparib treatment
Centr Georges Francois Leclerc9 个研究点 分布在 1 个国家目标入组 230 人开始时间: 2024年10月15日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 230
- 试验地点
- 9
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
François GHIRINGHELLI
Scientific
Centr Georges Francois Leclerc
研究点 (9)
Loading locations...
相似试验
已完成
1 期
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Aticaprant (JNJ-67953964)2023-503258-11-00Janssen - Cilag International48
招募中
1 期
EPITOME-1015-I: A phase I study to investigate the safety and tolerability of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcomaSynovial Sarcoma2024-516787-28-00Medigene AG20
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96